Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
Stopped early · Phase 1
Conditions studied: Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
In brief
This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart as a single agent and in combination in participants with relapsed and/or refractory solid or hematologic cancers, as well as newly diagnosed cancers, and an open-label, randomized study of aplitabart+FOLFIRI+bevacizumab.
Key facts
- Study ID
- NCT04553692
- Run by
- IGM Biosciences, Inc.
- People needed
- 272
- Starts
- 2020-09-23
- Expected to finish
- 2025-01-20
- Last updated by the study team
- 2025-03-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope Comprehensive Cancer Center — Duarte, California, United States
- Cancer and Blood Specialty Clinic (CBSC) — Los Alamitos, California, United States
- USC Norris — Los Angeles, California, United States
- UCLA — Los Angeles, California, United States
- UC Irvine Manchester Pavilion — Orange, California, United States
- UCSF — San Francisco, California, United States
- Rocky Mountain Cancer Centers — Denver, Colorado, United States
- SCRI at Healthone — Denver, Colorado, United States
- Yale Cancer Center — New Haven, Connecticut, United States
- Mayo Clinic — Jacksonville, Florida, United States
- FL Cancer Specialists - Lake Mary — Lake Mary, Florida, United States
- Memorial Cancer Institute — Pembroke Pines, Florida, United States
- Florida Cancer Specialists — Sarasota, Florida, United States
- Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana, United States
- Norton Cancer Institute — Louisville, Kentucky, United States
- Ochsner Cancer — Jefferson, Louisiana, United States
- Maryland Oncology Hematology, PA - Columbia — Columbia, Maryland, United States
- START Midwest — Grand Rapids, Michigan, United States
- Minnesota Oncology - Minneapolis Clinic — Minneapolis, Minnesota, United States
- Mayo Clinic — Minneapolis, Minnesota, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Gabrail Cancer Research — Canton, Ohio, United States
- Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
- Providence Portland Medical Center — Portland, Oregon, United States
- Mayo Clinic — Phoenix, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.